In this E-Book we discuss:
More about this E-Book
In developing immunotherapies, processes and biomarkers are made more complex by the highly heterogenous T cells that form the basis for the therapeutic product or drive the anti-tumor response in various checkpoint and antibody-based immunotherapies.
IsoPlexis provides actionable potency, safety, and patient-difference metrics by detecting highly potent single-cell functional subsets.
Download this eBook to learn how these technological advancements are drastically accelerating the development of novel immunotherapies.